




| | | | |
|--------------------------|--|--------------------|--------------------|
| | | EMLc | ATC codes: L01BC01 |
| Indication | Burkitt lymphoma including Burkitt leukaemia | ICD11 code: 2B55.6 | |
| INN | Cytarabine | | |
| Medicine type | Chemical agent | | |
| List type | Complementary (EML) (EMLc) | | |
| Formulations | Parenteral > General injections > unspecified: 100 mg in vial powder for injection ; 100 mg per mL in vial | | |
| EML status history | First added in 1979 (TRS 641) Changed in 2011 (TRS 965) Changed in 2015 (TRS 994) Changed in 2023 (TRS 1049) | | |
| Sex | All | | |
| Age | Also recommended for children | | |
| Therapeutic alternatives | The recommendation is for this specific medicine | | |
| Patent information | Patents have expired in most jurisdictions Read more about patents .  | | |
| Tags | Cancer | | |
| Wikipedia | Cytarabine  | | |
| DrugBank | Cytarabine  | | |

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional dose form of cytarabine (100 mg/mL in vial) to the EML and EMLc.

